Administration
PATIENT GROUP DIRECTION (PGD) FOR

CODEINE PHOSPHATE 30MG TABLETS

YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

Clinical Condition	
Indication	Opioid type analgesic for moderate acute pain relief
Inclusion criteria	Patients 12 years and over presenting in MIU with moderate to severe acute pain
Exclusion criteria If any of the following apply the PGD CANNOT be used and the patient must be referred to a prescriber	Pregnant and/or breast feeding Previous allergy to opiate based analgesics Children under 12 years of age Patients under the influence of alcohol. Acute respiratory depression (incl asthma attack & COPD), reduced respiratory reserve. Head injury (risk of raised intracranial pressure) Impaired level of consciousness Impaired hepatic or renal function History of convulsive disorders Risk of Paralytic ileus Patients taking MAOI medication within the last 14 days. History of opiate abuse. Prostatic hyperplasia or hypertrophy. Shock. Hypotension. Myasthenia Gravis. Gallstones Cardiac Arrythmias. Concomitant interacting drugs eg some antibiotics, ritonavir, ketoconazole, memantine. Full list in Appendix 1 of current BNF
Cautions - Seek further advice from doctor before proceeding and document advice	Caution should be exercised before giving a dose of codeine to a patient who has already received another opiate analgesic or tramadol in the previous 4 hours as the effects will be additive. Patients having recently taken other sedating medication eg. tricyclic antidepressants, benzodiazepines etc Elderly and debilitated
Further information	Ensure patient has not taken any over the counter medicines containing codeine (analgesic or anti-diarrhoeals)
Action if patient declines or is excluded	Refer to doctor or A & E as appropriate

Administration
PATIENT GROUP DIRECTION (PGD) FOR

CODEINE PHOSPHATE 30MG TABLETS

Drug Details	
Name, form & strength of medicine	Codeine Phosphate 30mg Tablets
Legal status	Prescription Only Medicine (POM)
Route/Method	ORAL
Dosage	30mg - 60mg (1-2 tablets) In the elderly and children aged 12-18, a 15mg dose may be preferable (half a tablet).
Frequency	Once only, single dose.
Quantity to administer	See under dosage
Side effects	Drowsiness, nausea and/or vomiting, dry mouth, sweating, headache, confusion, constipation
Advice to patient/carer	Patients should be advised not to drive until the effects have worn off (4 – 6 hours). Due to the introduction of Drug Driving laws please inform the patient that codeine is likely to affect their ability to drive, so they should not drive until it is known how it affects them. It is an offence to drive while under the influence of this medicine, unless you know it does not affect your ability to drive safely.
Follow up	With a clinician if necessary

Administration
PATIENT GROUP DIRECTION (PGD) FOR

CODEINE PHOSPHATE 30MG TABLETS

Staff Characteristics		
Professional qualifications	Nurses on the NMC Register	
Specialist competencies or qualifications	A registered MIU nurse who has undertaken appropriate training for working under PGDs for the supply and administration of medicines and in anaphylaxis management.	
Continuing education & training	It is the responsibility of the individual to keep up-to-date with clinical developments as part of their CPD.	
Referral Arrangements and Audit Trail		
Records/audit trail	Patient's name, address, date of birth, Contact details of GP (if registered), Diagnosis, Dose and form given, Advice given to patient (including side effects), Signature/name of staff who gave the medication, Details of any adverse drug reaction and actions taken including documentation in the patient's medical record, Referral arrangements (including self-care). Complete PGD log form.	
References/Resources and comments	Current versions of the SPC (Summary of Product Characteristics) and BNF(British National Formulary) and BNF for children	
Clinical Authorisation		
Lead Doctor	Dr John Devapriam, Medical Director Signature:  Date: 12/7/18	
Lead Pharmacist	Dr Alex Johnson, Prescribing Support Pharmacist Signature:  Date: 11/7/18	
Organisational Authorisation		
On behalf of Worcestershire Health & Care NHS Trust	Michelle Clarke, Director of Nursing & Quality Signature:  Date: 5/7/18	
Patient Group Direction Peer Reviewed by		
MIU nurses		

Administration
PATIENT GROUP DIRECTION (PGD) FOR

CODEINE PHOSPHATE 30MG TABLETS

Individual Authorisation

PGDs DO NOT REMOVE INHERENT PROFESSIONAL OBLIGATIONS OR ACCOUNTABILITY.

It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with their own Code of Professional Conduct.

Note to Authorising Managers: authorised staff should be provided with an individual copy of the clinical content of the PGD and a photocopy of the document showing their authorisation. Authorising managers should be sure that staff signed up to use the PGD have the necessary competence, training and knowledge to apply it.

I have read and understood the Patient Group Direction and agree to supply/administer this medicine only in accordance with this PGD. I confirm that I have the necessary competence, training and knowledge to apply it.

Name of Professional	Signature	Authorising Manager	Date